| pubmed-article:11358917 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11358917 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:11358917 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:11358917 | lifeskim:mentions | umls-concept:C0680854 | lld:lifeskim |
| pubmed-article:11358917 | lifeskim:mentions | umls-concept:C0022558 | lld:lifeskim |
| pubmed-article:11358917 | lifeskim:mentions | umls-concept:C1707959 | lld:lifeskim |
| pubmed-article:11358917 | lifeskim:mentions | umls-concept:C0595490 | lld:lifeskim |
| pubmed-article:11358917 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11358917 | pubmed:dateCreated | 2001-5-18 | lld:pubmed |
| pubmed-article:11358917 | pubmed:abstractText | This paper describes the introduction of the Malarone Donation Programme in KENYA: Using a policy analysis approach it illustrates the political nature of donation programmes and how they are affected by a large and varied group of national, regional and international stakeholders, with different levels of influence and experience. The paper shows that interaction between these different groups may affect the development and implementation of the donation programme. It ends by raising some more general questions about public/private partnerships and corporate donation programmes, and their potential impact on national drug policies. | lld:pubmed |
| pubmed-article:11358917 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11358917 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:citationSubset | H | lld:pubmed |
| pubmed-article:11358917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11358917 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11358917 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11358917 | pubmed:issn | 0268-1080 | lld:pubmed |
| pubmed-article:11358917 | pubmed:author | pubmed-author:SnowRR | lld:pubmed |
| pubmed-article:11358917 | pubmed:author | pubmed-author:WaldWW | lld:pubmed |
| pubmed-article:11358917 | pubmed:author | pubmed-author:BruggiMM | lld:pubmed |
| pubmed-article:11358917 | pubmed:author | pubmed-author:ShrettaRR | lld:pubmed |
| pubmed-article:11358917 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11358917 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:11358917 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11358917 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11358917 | pubmed:pagination | 161-70 | lld:pubmed |
| pubmed-article:11358917 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:meshHeading | pubmed-meshheading:11358917... | lld:pubmed |
| pubmed-article:11358917 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11358917 | pubmed:articleTitle | A political analysis of corporate drug donations: the example of Malarone in Kenya. | lld:pubmed |
| pubmed-article:11358917 | pubmed:affiliation | Kenya Medical Research Institute (KEMRI)/Wellcome Trust, Collaborative Programme, Nairobi, Kenya. | lld:pubmed |
| pubmed-article:11358917 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11358917 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11358917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11358917 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11358917 | lld:pubmed |
